TSC Alliance and Apertura Gene Therapy Complete Preclinical Pilot Study Evaluating AAV Gene Therapy Approach Designed for TSC1

Phase 1TSC1 AAV Gene TherapyTSC2 AAV Gene TherapyPositive

AI Analysis

Summary

TSC Alliance and Apertura Gene Therapy completed a preclinical pilot study evaluating an AAV gene therapy approach designed for TSC1, with plans to continue preclinical evaluation of TSC1 and TSC2 programs using Apertura's TfR1 CapX capsid technology.

Outcome Details

Preclinical pilot study completed evaluating AAV gene therapy approach for TSC1

Importance:3/10

Sentiment:

0.50

gene therapyAAVTSC1TSC2TfR1 CapX capsidpreclinicalrare disease

Read the original article

Published by PR Newswire Pharma on July 30, 2026 12:00 PM

Read Original